Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
21 June 2021 | Story Lacea Loader | Photo Kaleidoscope Studios (Sonia Small)
Prof Francis Petersen
Prof Francis Petersen
The Council of the University of the Free State (UFS) unanimously approved the re-appointment of Prof Francis Petersen for a second five-year term as Rector and Vice-Chancellor of the UFS, as from 31 March 2022 to 1 April 2027. The decision was made during Council’s second scheduled meeting for the year, which took place virtually on 18 June 2021.

Council appreciation for exceptional leadership
“Prof Petersen’s first term was characterised by exceptional leadership and the Council has significant appreciation for the work that he has done and his accomplishments to date. Since his appointment on 1 April 2017 and under his leadership, the UFS has excelled in a number of key areas,” said Dr Willem Louw, Chairperson of the UFS Council.

Excellence, inclusivity, innovation, academic freedom, a particular focus and emphasis on critical enquiry, social responsiveness, integrity, and humaneness have been the value trademarks by which Prof Petersen operates. Early in his term – through a well-structured, thought-through, and consultative approach – he produced the strategic framework for the UFS for the period 2018 to 2022, the key performance areas of which have been implemented in most cases or are nearing completion.

“Prof Petersen has put forward a compelling set of drivers for his second term and indicated that he specifically intends to focus on and elevate the teaching and learning, research and internationalisation, and engaged scholarship portfolios of the university. On behalf of the Council, I wish him all the best with the second term and look forward with great expectation to what he and his executive team will achieve to further advance the UFS nationally and internationally,” said Dr Louw.

“I am humbled and honoured by the expression of confidence in me; it is a privilege to  continue leading one of the greatest universities in the country on its new journey. I will continue to do my utmost to build a strong institution that belongs to everyone, and want to thank our staff, students, and valued stakeholders for their continued support,” said Prof Petersen.

Achievements during first term
The UFS’ achievements during Prof Petersen’s first term include the implementation of an Integrated Transformation Plan (ITP) (towards social justice); the UFS Strategic Plan (towards expanding the scope of transformation); the Vice-Chancellor Strategic Projects (towards a high-performance institution); the institutional Risk Management Committee (towards risk management and risk philosophy); and the institutional Multi-Stakeholder Group (towards an inclusive institutional culture).

Further highlights include the development of differentiated research, internationalisation, and innovation strategies for the UFS; the development of Project Caring in the domain of the Unit for Institutional Change and Social Justice; facilitating an institutional governance project; development of a strategy and plans for a Digital Scholarship Centre; the development of proactive relationships with the Department of Higher Education, Science and Innovation and the National Student Financial Aid Scheme (NSFAS); and the establishment of a Reputation Management Forum to assist in improving the reputation and profile of the UFS.

Vision for the second term
Prof Petersen’s vision for his second term includes the continuation of the ITP, with a primary focus on the social justice imperative and ensuring the completion of all the deliverables; using the sustainable development goals (SDGs) as basis of the response as to how the UFS will affect society positively; using digitisation as key focus in determining how the academic project will be delivered, supported and how it is interfacing with the external environment; raising the external profile of the UFS through alumni, foundations, donors, and strategic communication as critical drivers; and to continue participating and further advancing national and global discourses.




News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept